Back to results
US 2021/0069290 A1Published application
Treatment of Inflammation, Autoimmune, and Neurodegenerative Disorders with Immunosuppressive Tat Derivative Polypeptides
AssigneePIN Pharma, Inc.
InventorsJoshua Goldberg, Colin Bier, Christoph Hotz-Behofsits, Sophie Hanscom
Life of this patent
Estimating the term…
Abstract
The present specification provides immunosuppressive Tat derivative polypeptides, compositions, and methods of using such polypeptides and compositions to treat an autoimmune disease, an inflammation-associated disease and/or a neurodegenerative disease.
Claims7
An immunosuppressive trans-activator of transcription (Tat) derivative polypeptide comprising an amino acid sequence comprising the following domains in the indicated order:
- a transcription factor (TF) domain comprising SEQ ID NO:
- 39;
- a cysteine-rich region comprising SEQ ID NO:
- 65;
- and
- a C-terminal region comprising amino acid residues 18-70 of SEQ ID NO:
- 42.
4 more elements
Dependencies are inferred from the claim text.